UA93538C2 - Aurora kinase modulators and method of use - Google Patents

Aurora kinase modulators and method of use

Info

Publication number
UA93538C2
UA93538C2 UAA200810586A UAA200810586A UA93538C2 UA 93538 C2 UA93538 C2 UA 93538C2 UA A200810586 A UAA200810586 A UA A200810586A UA A200810586 A UAA200810586 A UA A200810586A UA 93538 C2 UA93538 C2 UA 93538C2
Authority
UA
Ukraine
Prior art keywords
compounds
kinase
influencing
disease states
modulating
Prior art date
Application number
UAA200810586A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Виктор Дж. Си
Холли Л. Дик
Бингфан Дю
Стефани Д. Геунс-Мейер
Брайян Л. Ходоус
Ханх Hxo Нгуйэн
Филип P. Оливиэри
Винод Ф. Пател
Карина Ромеро
Лори Шенкел
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of UA93538C2 publication Critical patent/UA93538C2/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to chemical compounds having a general formula (I) wherein A, A, C, C, D, L, L, Z and Rare defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of kinase.
UAA200810586A 2006-01-23 2007-01-22 Aurora kinase modulators and method of use UA93538C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76167506P 2006-01-23 2006-01-23

Publications (1)

Publication Number Publication Date
UA93538C2 true UA93538C2 (en) 2011-02-25

Family

ID=40538757

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200810586A UA93538C2 (en) 2006-01-23 2007-01-22 Aurora kinase modulators and method of use

Country Status (3)

Country Link
CN (1) CN101405282B (en)
UA (1) UA93538C2 (en)
ZA (1) ZA200806627B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
EP2818170B1 (en) * 2009-09-11 2018-12-05 Amgen, Inc N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
CN103664737A (en) * 2012-09-25 2014-03-26 杨子娇 Compounds for treating narrow chamber angle and application thereof
CN112898292A (en) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 Novel aurora kinase inhibitor and use thereof
CN111039940B (en) * 2019-12-31 2022-10-21 北京鑫开元医药科技有限公司 Aurora A kinase inhibitor, preparation method, pharmaceutical composition and application thereof

Also Published As

Publication number Publication date
ZA200806627B (en) 2009-10-28
CN101405282A (en) 2009-04-08
CN101405282B (en) 2015-03-25

Similar Documents

Publication Publication Date Title
MX2009010517A (en) Aurora kinase modulators and method of use.
TNSN08310A1 (en) Aurora kinase modulators and method of use
MX2010010151A (en) Aurora kinase modulators and method of use.
ATE478861T1 (en) MULTICYCLIC CONNECTION AND METHOD OF USE
MX2021007158A (en) Heteroaryl amides useful as kif18a inhibitors.
MX2021007157A (en) Heteroaryl amides useful as kif18a inhibitors.
MXPA06012613A (en) Protein kinase modulators and method of use.
JOP20210154B1 (en) Kif18a inhibitors
MX2022001302A (en) Pyridine derivatives as kif18a inhibitors.
MX2021007104A (en) Kif18a inhibitors.
MX2022001181A (en) Kif18a inhibitors.
MX2009004060A (en) Triazolo-pyridazine protein kinase modulators.
MEP3808A (en) Pyrimidinyl aryl urea derivatives being fgf inhibitors
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
UA95244C2 (en) Compounds and methods for kinase modulation, and indications therefor
IN2014KN02886A (en)
UA104849C2 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as inhibitors of janus kinases
EA200970738A1 (en) AKT ACTIVITY INHIBITORS
TW200607513A (en) Certain chemical entities, compositions, and methods
MX2007008065A (en) Compositions and methods for modulating gene expression using self-protected oligonucleotides.
MX2008011258A (en) Quinazoline derivatives as phosphodiesterase 10 inhibitors.
SI2054418T1 (en) Dihydrothieno pyrimidines as akt protein kinase inhibitors
ATE493418T1 (en) DIHYDROFUROPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS
SG162753A1 (en) Methods of treating cancer and other conditions or disease states using lfmau and ldt
UA100545C2 (en) Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors